4th Annual Heart Team Summit

Friday, October 21, 2022, 7:00 AM - Saturday, October 22, 2022, 12:00 PM, Four Seasons St. Louis, St. Louis, MO


A Heart Team is now a standard treatment approach for complex cardiovascular patients. The Heart Team consists of cardiologists, cardiac surgeons, nurses and other health care specialists. This includes regular meetings to make consensus treatment recommendations for conditions including obstructive coronary artery disease and valvular heart conditions. This meeting will provide expert lectures and case presentations geared toward health care professionals who may be part of a Heart Team. Included with be the latest innovations as well as standard treatments, including transcatheter valvular heart therapies and coronary revascularization strategies.

1. Describe the concept of the Heart Team, including the key components and functionality
2. List transcatheter options to address heart valve pathology including aortic, mitral, tricuspid and pulmonic stenosis and regurgitation
3. Describe the latest interventional techniques and therapies for structural heart disease and congenital heart disease
4. Recognize patient selection and appropriate patient referral for surgical versus percutaneous/transcatheter mitral and aortic valve intervention
5. Apply various diagnostic technologies including transthoracic echocardiography, intracardiac echocardiography, TEE, CT, and CMR to guide management of valvular heart disease
6. Describe the differences in outcomes in valvular and coronary pathology as it refers to men and women.
7. Describe the racial disparities encountered in cardiovascular health
8. Utilize the various hemodynamic support and interventional/surgical tools to assist in the management of cardiogenic shock
9. Identify the indications for LA appendage closure and the available and emerging technologies to manage the left atrial appendage and how it can mitigate stroke.
10. Summarize the latest developments and the current guidelines on the appropriate use of surgical and percutaneous coronary revascularization.

Early Bird Rates (through 10/1/2022):
Early Bird In-person Attendance: $150
Early Bird Virtual Attendance: $50
Fellow Attendance (in-person or virtual)*: Complimentary

Regular Rates (after 10/1/2022):
In-person Attendance: $195
Virtual Attendance: $65
Fellow Attendance (in-person or virtual)*: Complimentary

*Fellows may be asked to provide a letter from their Program Director.

NM Faculty/Staff are encouraged to use "EdAssist" funds to reimburse their registration fees.  Please contact your Manager for additional information.

Washington University and Ascension Employees are encouraged to check for similar funds with their Managers.

Registration will close on:

October 18, 2022 for in-person attendance

October 22, 2022 for virtual attendance

Cancellations/Refunds

Cancellations must be made in writing to [email protected]. The paid registration fee will be refunded if cancellation is received by September 23, 2022. No refunds will be issued after this date.

Please contact Karen Laguatan at [email protected] with any questions.

The Northwestern University Feinberg School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

The Northwestern University Feinberg School of Medicine designates this live activity for a maximum of 11.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMA PRA Category 1 Credits™ (11.50 hours), Non-Physician Attendance (11.50 hours), ABIM MOC Part 2 (11.50 hours)

Mitigation of Relevant Financial Relationships

Feinberg School of Medicine - adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.